Ironwood Pharmaceuticals Inc (IRWD) Stock AnalysisIRWDIronwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ironwood Pharmaceuticals Inc (IRWD) currently trades at $3.46, with a low RSI of 33.05 suggesting it is oversold. However, the stock has seen a significant insider selling increase of 22659.51%, indicating potential lack of confidence from insiders. Despite a strong year-over-year change of +112.27%, the recent 20-day change of -16.22% and negative sentiment around leadership changes suggest caution. Therefore, it may be wise to hold rather than buy at this time.

11 analysts cover IRWD: 5 rate it Buy, 5 Hold and 1 Sell. The average price target is 6.23.